Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy.
The current standard of care for hepatitis C virus (HCV) infection - combination therapy with pegylated interferon and ribavirin - elicits sustained responses in only ∼50% of the patients treated. No alternatives exist for patients who do not respond to combination therapy. Addition of ribavirin sub...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2011-02-01
|
| Series: | PLoS Computational Biology |
| Online Access: | http://europepmc.org/articles/PMC3033369?pdf=render |